World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
27384
World Ranking
10191
National Ranking
362

Andrés J.M. Ferreri publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrés J.M. Ferreri sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 487 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrés J.M. Ferreri D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrés J.M. Ferreri sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrés J.M. Ferreri is affiliated with Vita-Salute San Raffaele University in Italy. Their research primarily spans the field of Medicine, with a focus on several key subfields including Pathology and Forensic Medicine, Oncology, Genetics, Neurology, and Immunology. The scientist's work centers heavily on lymphoma, particularly on its diagnosis and treatment, as well as research on chronic lymphocytic leukemia and CAR-T cell therapy.

Their scholarly contributions include a significant number of publications in notable venues such as Hematological Oncology, Blood, Blood Advances, British Journal of Haematology, and UNC Libraries. Frequent coauthors in their research include Maurilio Ponzoni, Teresa Calimeri, Carlo Visco, Emanuele Zucca, and Luca Arcaini.

Among the recent papers authored or coauthored by Andrés J.M. Ferreri are:

  • Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial (2021, Nature Medicine)
  • Primary central nervous system lymphoma (2023, Nature Reviews Disease Primers)
  • Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) (2021, Neuro-Oncology)
  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022, Leukemia)
  • European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) (2022, Neuro-Oncology)

The main topics addressed across Andrés J.M. Ferreri's body of work include:

  • Lymphoma Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Glioma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Immune Cell Function and Interaction

These research interests are closely linked to their multidisciplinary expertise in related medical and biological sciences, integrating clinical approaches with immunological and genetic perspectives. The scientist's publication record reflects ongoing contributions to the advancement of understanding and treating complex hematological malignancies and neurological cancers.

Best Publications

  • Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini

  • High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

    Andrés J. M. Ferreri;Michele Reni;Marco Foppoli;Maurizio Martelli

  • Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas

    Andrés J. M. Ferreri;Massimo Guidoboni;Maurilio Ponzoni;Carlo De Conciliis

  • Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

    Emanuele Zucca;Annarita Conconi;Ennio Pedrinis;Sergio Cortelazzo

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

    Shimin Hu;Zijun Y. Xu-Monette;Alexander Tzankov;Tina Green

  • Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting

    Maurilio Ponzoni;Andrés J.M. Ferreri;Elías Campo;Fabio Facchetti

  • Diffuse large B-cell lymphoma.

    Maurizio Martelli;Andrés J.M. Ferreri;Claudio Agostinelli;Alice Di Rocco

  • Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

    Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri

  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

    Zijun Y. Xu-Monette;Lin Wu;Carlo Visco;Yu Chuan Tai

  • Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

    Khê Hoang-Xuan;Eric Bessell;Jacoline Bromberg;Andreas F Hottinger

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.

    Giovanni Martinelli;Daniele Laszlo;Andrés J M Ferreri;Giancarlo Pruneri

  • Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002

    Andrés J.M. Ferreri;Lauren E. Abrey;Jean Yves Blay;Bettina Borisch

  • Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

    Markus Raderer;Barbara Kiesewetter;Andrés J. M. Ferreri

  • Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group

    Tamara N. Shenkier;Jean Yves Blay;Brian Patrick O'Neill;Philip Poortmans

  • Regression of Ocular Adnexal Lymphoma After Chlamydia Psittaci–Eradicating Antibiotic Therapy

    Andrés J M Ferreri;Maurilio Ponzoni;Massimo Guidoboni;Carlo De Conciliis

  • First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

    Umberto Vitolo;Annalisa Chiappella;Andrés J.M. Ferreri;Maurizio Martelli

  • Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients

    Pier Luigi Zinzani;Maurizio Martelli;Marilena Bertini;Alessandro M Gianni

  • Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

    Carlo Visco;Alexander Tzankov;Zijun Y. Xu-Monette;Roberto N. Miranda

Frequent Co-Authors

Maurilio Ponzoni
Maurilio Ponzoni Vita-Salute San Raffaele University
Emanuele Zucca
Emanuele Zucca Universita della Svizzera Italiana
Miguel A. Piris
Miguel A. Piris Instituto de Salud Carlos III
Govind Bhagat
Govind Bhagat Columbia University
Eric D. Hsi
Eric D. Hsi Cleveland Clinic
Claudio Doglioni
Claudio Doglioni Vita-Salute San Raffaele University
Youli Zu
Youli Zu Houston Methodist
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Santiago Montes-Moreno
Santiago Montes-Moreno Instituto de Investigación Marqués de Valdecilla

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine isn’t limited to becoming a doctor. A variety of online degrees and accelerated career paths in healthcare are gaining popularity, offering flexible options for students from all backgrounds.

Those interested in administrative roles may consider enrolling in healthcare administration accelerated degree programs. These offer quick, focused training for leadership positions in medical facilities.

For students wanting to work in clinical settings without years of schooling, nursing programs present various entry points. You can pursue rn to fnp programs if you wish to advance from an associate degree in nursing to a nurse practitioner role. If you’re concerned about entrance exams, there are nursing school that don't require teas or HESI exams, eliminating a common barrier.

Additionally, non-clinical fields like medical billing and coding can be a fast route to employment, with many medical billing and coding online schools that accept financial aid making the required credential accessible to most students.

These alternative degrees and career pathways can help you enter the healthcare field quickly, often with less financial and time investment compared to traditional medical programs.

Best Scientists Citing Andrés J.M. Ferreri

Trending Scientists

Recently Published Articles